Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)19.53bn
- Net income in USD10.86bn
- Incorporated2008
- Employees3.08k
- LocationBioNTech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://biontech.de/
Mergers & acquisitions
| Acquired company | 22UA:GER since announced | Transaction value |
|---|---|---|
| Novartis Singapore Pharmaceutical Manufacturing Pte Ltd-Gpm Manufacturing Site | 8.30% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seagen Inc | 1.86bn | -636.77m | 22.47bn | 2.68k | -- | 7.94 | -- | 12.05 | -3.46 | -3.46 | 10.14 | 15.23 | 0.4908 | 1.42 | 4.27 | 696,864.70 | -16.76 | -5.22 | -20.63 | -6.00 | 79.16 | 87.67 | -34.16 | -9.78 | 3.30 | -142.61 | 0.00 | -- | -27.63 | 30.36 | -209.91 | -- | 13.46 | -- |
| Horizon Therapeutics PLC | 3.70bn | 574.26m | 22.86bn | 2.10k | 41.48 | 4.58 | 23.75 | 6.18 | 2.43 | 2.43 | 15.68 | 22.01 | 0.4198 | 4.31 | 5.21 | 1,958,455.00 | 6.51 | 3.93 | 7.21 | 4.64 | 75.12 | 71.37 | 15.51 | 10.98 | 3.74 | 9.49 | 0.3376 | 0.00 | 46.63 | 26.88 | 37.12 | -- | 37.25 | -- |
| Alnylam Pharmaceuticals, Inc. | 960.92m | -1.18bn | 27.10bn | 1.67k | -- | -- | -- | 28.20 | -9.77 | -9.77 | 7.95 | -0.5499 | 0.2743 | 1.45 | 6.86 | 577,127.90 | -33.74 | -32.56 | -42.04 | -37.94 | 83.85 | -- | -123.02 | -223.64 | 3.33 | -2.76 | 1.07 | -- | 71.31 | 78.07 | 0.6358 | -- | 3.42 | -- |
| Gartner Inc | 5.28bn | 760.34m | 28.15bn | 16.60k | 38.42 | -- | 29.47 | 5.33 | 9.27 | 9.27 | 64.37 | -0.8201 | 0.7807 | -- | 5.11 | 317,918.80 | 11.25 | 4.12 | 20.19 | 7.06 | 69.34 | 65.00 | 14.41 | 6.65 | -- | 15.86 | 1.03 | -- | 15.48 | 14.13 | 197.50 | 32.60 | 3.71 | -- |
| DuPont de Nemours Inc | 14.18bn | 1.16bn | 34.98bn | 28.00k | 30.77 | 1.40 | 14.04 | 2.47 | 2.29 | 3.63 | 27.84 | 50.15 | 0.3148 | 3.54 | 5.49 | 506,571.40 | 2.71 | -0.2227 | 3.11 | -0.2892 | 35.05 | 31.60 | 8.62 | -1.61 | 1.99 | 5.11 | 0.3173 | -- | 16.15 | -19.13 | 172.14 | -15.09 | -25.20 | -26.30 |
| Iqvia Holdings Inc | 14.31bn | 1.18bn | 40.96bn | 83.00k | 35.89 | 7.66 | 18.39 | 2.86 | 6.15 | 6.15 | 74.43 | 28.78 | 0.593 | -- | 5.76 | 181,101.30 | 4.94 | 1.77 | 6.25 | 2.14 | 34.72 | 34.30 | 8.34 | 3.64 | -- | 5.19 | 0.6986 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| BioNTech SE - ADR | 19.53bn | 10.86bn | 41.13bn | 3.08k | 3.95 | 2.13 | 3.74 | 2.11 | 42.94 | 42.94 | 76.73 | 79.68 | 1.01 | 9.87 | 2.07 | 6,338,052.00 | 55.96 | -- | 73.64 | -- | 81.71 | -- | 55.60 | -- | 5.30 | -- | 0.0147 | -- | 3,834.42 | -- | 67,622.73 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 30 Sep 2022 | 7.25m | 2.98% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 2022 | 4.38m | 1.80% |
| PRIMECAP Management Co.as of 30 Sep 2022 | 4.19m | 1.73% |
| Flossbach von Storch AGas of 30 Sep 2022 | 3.36m | 1.38% |
| Artisan Partners LPas of 30 Sep 2022 | 2.23m | 0.92% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2022 | 1.62m | 0.67% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 1.47m | 0.61% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2022 | 1.26m | 0.52% |
| DWS Investment GmbHas of 30 Sep 2022 | 605.63k | 0.25% |
| Pictet Asset Management SAas of 30 Sep 2022 | 585.13k | 0.24% |
